Acute Myeloid Leukemia is a fast‑growing blood cancer that starts in the bone marrow, the spongy tissue inside bones where blood cells are made. In this condition, abnormal cells grow quickly and crowd out normal blood cells, leading to symptoms such as fatigue, easy bruising, and infections. The study tests a combination of three medicines: an antibody called Pivekimab Sunirine (referred to as PVEK), a pill called Venetoclax that is taken oral, and a drug called Azacitidine that is given intravenous or under the skin.
The main goal is to see whether adding PVEK to the standard pair of Venetoclax and Azacitidine can increase the rate of complete remission and help patients live longer, measured as overall survival. Participants will receive the medicines in regular cycles over several months, with clinic visits for dosing, blood tests, and health questionnaires. The study is divided into two parts: an early stage that looks primarily at remission rates, and a later stage that also compares how long patients survive.
Throughout the trial, doctors will watch for side effects and any changes in how the disease behaves. Patients will have routine check‑ups, lab work, and imaging as needed to ensure safety and to track the disease. After the treatment period, follow‑up visits continue for a period to monitor long‑term outcomes and quality of life.
Austria 
France 
Spain 
